Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Nov;65 Suppl 3(Suppl 3):iii29-33.
doi: 10.1136/ard.2006.058529.

Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis

M I Koenders  1 , L A B Joosten, W B van den Berg
Affiliations
Review

Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis

M I Koenders et al. Ann Rheum Dis. 2006 Nov.

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by chronic joint inflammation and destruction. Interleukin (IL)-17 is a T cell cytokine expressed in the synovium and synovial fluid of patients with RA. IL-17 is a potent inducer of various cytokines such as tumour necrosis factor (TNF) and IL-1. IL-17 has been shown to have additive or even synergistic effects with TNF and IL-1 during the induction of cytokine expression and joint damage in vitro and in vivo. TNFalpha and IL-1 are considered powerful targets in the treatment of RA because of their leading role in driving the enhanced production of cytokines, chemokines, and degradative enzymes. Besides anti-TNF and anti-IL-1 therapies, whose clinical efficacy is now established, new targets have been proposed for RA which is not responding to conventional treatments. This paper discusses the role of IL-17 in experimental arthritis and its interrelationship with TNF and IL-1, currently the most targeted cytokines in the treatment of RA. IL-17 is involved in both initiation and progression of murine experimental arthritis. Studies have shown that IL-17 not only synergises with TNF, but also enhances inflammation and destruction independent of IL-1 and TNF. On the basis of these studies, the authors propose IL-17 as an interesting additional target in the treatment of RA.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none declared

References

    1. Harrington L E, Hatton R D, Mangan P R, Turner H, Murphy T L, Murphy K M.et al Interleukin 17‐producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 200561123–1132. - PubMed
    1. Park H, Li Z, Yang X O, Chang S H, Nurieva R, Wang Y H.et al A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 200561133–1141. - PMC - PubMed
    1. Chabaud M, Durand J M, Buchs N, Fossiez F, Page G, Frappart L.et al Human interleukin‐17: a T cell‐derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 199942963–970. - PubMed
    1. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska‐Pietrzak K, Klimczak E, Chwalinska‐Sadowska H.et al High levels of IL‐17 in rheumatoid arthritis patients: IL‐15 triggers in vitro IL‐17 production via cyclosporin A‐sensitive mechanism. J Immunol 20001642832–2838. - PubMed
    1. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S.et al IL‐17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 19991031345–1352. - PMC - PubMed

Publication types

MeSH terms